Biomarker-Guided Treatment Selection in RA | Q2 2026
This educational material is in development by independent expert faculty. Support for this activity is being sought through unrestricted educational grants. If supported, supporters will have no role in faculty selection, content development, conclusions, or dissemination.
Status: In development; support not yet awarded.
Practical decision framework for evaluating biomarker panel utility in rheumatoid arthritis (RA), including evidence-strength labels and interpretation guardrails.
Covers: evidence appraisal checklist, common misinterpretations, and decision points where testing may or may not inform evaluation. This material does not provide treatment recommendations.
Content forthcoming
Expected ~30 days post-session